Moser Wealth Advisors LLC Decreases Position in AstraZeneca PLC (NASDAQ:AZN)

Moser Wealth Advisors LLC reduced its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 2.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,745 shares of the company’s stock after selling 300 shares during the quarter. Moser Wealth Advisors LLC’s holdings in AstraZeneca were worth $770,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB boosted its position in AstraZeneca by 5.6% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 75,651 shares of the company’s stock valued at $4,957,000 after buying an additional 4,004 shares during the last quarter. Apollon Wealth Management LLC lifted its stake in shares of AstraZeneca by 2.2% in the fourth quarter. Apollon Wealth Management LLC now owns 15,796 shares of the company’s stock worth $1,035,000 after acquiring an additional 347 shares in the last quarter. Quattro Financial Advisors LLC boosted its holdings in AstraZeneca by 330.0% in the fourth quarter. Quattro Financial Advisors LLC now owns 4,300 shares of the company’s stock valued at $282,000 after purchasing an additional 3,300 shares during the last quarter. Generate Investment Management Ltd acquired a new stake in AstraZeneca during the 4th quarter valued at approximately $7,918,000. Finally, Golden State Wealth Management LLC purchased a new stake in AstraZeneca during the 4th quarter worth approximately $55,000. 20.35% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Performance

Shares of AZN opened at $71.99 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The business’s fifty day moving average price is $67.46 and its 200 day moving average price is $73.60. The stock has a market capitalization of $223.25 billion, a PE ratio of 31.85, a price-to-earnings-growth ratio of 1.20 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.55%. Equities research analysts forecast that AstraZeneca PLC will post 4.66 EPS for the current year.

AstraZeneca Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Monday, March 24th. Investors of record on Friday, February 21st will be issued a $1.03 dividend. This is an increase from AstraZeneca’s previous semi-annual dividend of $0.49. The ex-dividend date of this dividend is Friday, February 21st. This represents a dividend yield of 2%. AstraZeneca’s dividend payout ratio (DPR) is 43.36%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.